https://scholars.lib.ntu.edu.tw/handle/123456789/484114
標題: | Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma | 作者: | YU-YUN SHAO Huang C. PO-CHIN LIANG ZHONG-ZHE LIN |
公開日期: | 2010 | 出版社: | Blackwell Publishing Ltd | 卷: | 6 | 期: | 2 | 起(迄)頁: | 80-88 | 來源出版物: | Asia-Pacific Journal of Clinical Oncology | 摘要: | Treatment of advanced hepatocellular carcinoma (HCC) remains a significant problem for clinicians. Sorafenib, the only approved agent, improves survival rate, but is associated with a low tumor response rate. Alternative approaches for the treatment of advanced HCC are urgently needed. Hepatic arterial infusion of chemotherapy (HAIC) is a promising modality for the treatment of advanced HCC. Since its introduction, there have been improvements in implantable pumps, in catheter implantation and in the convenience and safety of HAIC in general. Numerous clinical studies have shown that HAIC provides moderate therapeutic efficacy with substantially favorable toxicity profiles in selected patient groups with advanced HCC. However, the lack of large randomized studies means that HAIC is not yet a well-established treatment for advanced HCC. We believe there is an urgent need for the further investigation of HAIC for the treatment of advanced HCC. ? 2010 Blackwell Publishing Asia Pty Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954139207&doi=10.1111%2fj.1743-7563.2010.01287.x&partnerID=40&md5=25ddd18b593714d51edf3dc65e3800f1 https://scholars.lib.ntu.edu.tw/handle/123456789/484114 |
ISSN: | 1743-7555 | DOI: | 10.1111/j.1743-7563.2010.01287.x | SDG/關鍵字: | alpha interferon; anthracycline; carboplatin; cisplatin; doxorubicin; epirubicin; etoposide; fluorouracil; folinate calcium; folinic acid; macrosalb tc 99m; mitomycin C; peginterferon alpha; sorafenib; antineoplastic agent; advanced cancer; angiography; anorexia; artery dissection; artery occlusion; artery puncture; artificial embolism; axillary artery; bone marrow suppression; cancer combination chemotherapy; cancer survival; catheter complication; catheter infection; catheterization; celiac artery; daily life activity; depression; diarrhea; drug dose escalation; drug efficacy; drug infusion; drug safety; femoral artery; first pass effect; flow rate; fluoroscopy; gastritis; gastroduodenal artery; hematoma; hepatic artery; human; hypertransaminasemia; infection; infusion pump; laparotomy; leukopenia; liver cell carcinoma; liver cirrhosis; liver dysfunction; liver function; liver metastasis; minipump; nausea; neutropenia; patient selection; peptic ulcer; portal vein thrombosis; priority journal; proper hepatic artery; review; shunting; subclavian artery; superior mesenteric artery; survival rate; systemic therapy; thrombocytopenia; treatment response; Carcinoma, Hepatocellular; intraarterial drug administration; Liver Neoplasms; pathology; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。